THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. CASCAIS, Portugal, April 23, 2026 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“Pulsar” or the “Company”), a primary helium company, understands that a third-party broker has falsely circulated communications including terms of a private placement involving the Company. These communications have no basis. The Company is currently reviewing...

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio replay of the call will be available through Thursday, May 14, 2026, and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005...

Announcement no. 04/2026Inside information Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower market recovery in the skin substitutes outpatient setting and a resulting lower growth outlook for Kerecis. The Group organic growth is now expected to be 5-6%, from previously around 7%. The EBIT growth in constant currencies before special items is now expected to be around 5%, from previously around 7%. Return on invested capital after tax before special items is now expected around 15%. Key financial figures and developments in Q2Group organic growth was 6% in Q2 and EBIT1 growth in constant currencies was 6%. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice & Respiratory Care 8%, Wound & Tissue...

On 05.12.2025 the subsidiary of AS PRFoods (registry code 11560713) Saaremere Kala AS (registry code  11310040, hereinafter “Seller“) signed an agreement (the “SPA”) for the sale of its 100% shareholding in Saare Kala Tootmine OÜ (registry code 10377013, hereinafter “SKT“) and transfer of claims arising from shareholder loans and an inventory loan provided to SKT to the Latvian company Brīvais Vilnis A/S (Latvian registry code: 40003056186, hereinafter “Buyer“) (the “Transaction”). The main terms of the relevant Transaction and preconditions for closing thereof were disclosed in a stock exchange announcement published by AS PRFoods on 05.12.2025 “Conclusion of share sale agreement of the share of Saare Kala Tootmine OÜ and the proposal to the shareholders of AS PRFoods to adopt shareholders’ resolutions...

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information  FDA Does not Request Additional Clinical Data Company Intends to Resubmit Application Following Resolution of Cited Items PRINCETON, N.J., April 23, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company’s New Drug Application (NDA) for GTx-104 for the treatment of patients with...